- Home
- AIP vs ITOS Comparison
AIP vs ITOS Comparison
Compare AIP & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- ITOS
- Stock Information
- Founded
- AIP 2003
- ITOS 2011
- Country
- AIP United States
- ITOS United States
- Employees
- AIP N/A
- ITOS N/A
- Industry
- AIP Semiconductors
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIP Technology
- ITOS Health Care
- Exchange
- AIP Nasdaq
- ITOS Nasdaq
- Market Cap
- AIP 336.2M
- ITOS 381.2M
- IPO Year
- AIP 2021
- ITOS 2020
- Fundamental
- Price
- AIP $9.09
- ITOS $10.16
- Analyst Decision
- AIP Strong Buy
- ITOS Hold
- Analyst Count
- AIP 3
- ITOS 6
- Target Price
- AIP $15.00
- ITOS $10.60
- AVG Volume (30 Days)
- AIP 628.3K
- ITOS 914.0K
- Earning Date
- AIP 07-31-2025
- ITOS 08-07-2025
- Dividend Yield
- AIP N/A
- ITOS N/A
- EPS Growth
- AIP N/A
- ITOS N/A
- EPS
- AIP N/A
- ITOS N/A
- Revenue
- AIP $61,309,000.00
- ITOS $35,000,000.00
- Revenue This Year
- AIP $19.82
- ITOS N/A
- Revenue Next Year
- AIP $17.29
- ITOS N/A
- P/E Ratio
- AIP N/A
- ITOS N/A
- Revenue Growth
- AIP 14.68
- ITOS 177.89
- 52 Week Low
- AIP $5.46
- ITOS $4.80
- 52 Week High
- AIP $12.64
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- AIP 58.43
- ITOS 67.13
- Support Level
- AIP $8.66
- ITOS $9.95
- Resistance Level
- AIP $10.11
- ITOS $10.20
- Average True Range (ATR)
- AIP 0.68
- ITOS 0.16
- MACD
- AIP 0.02
- ITOS -0.10
- Stochastic Oscillator
- AIP 53.42
- ITOS 84.75
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.